Efficacy of <scp>COVID</scp>‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France

Derdevet, Julien; Ranque, Brigitte; Khimoud, Djamal; Joseph, Laure; Michon, Adrien; Flamarion, Edouard; Lafont, Emmanuel; Corbasson, Anne; Pouchot, Jacques; Arlet, Jean‐Benoît; Cheminet, Geoffrey

doi:10.1111/ejh.14034

Cited by 4 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study found that the most common presenting symptom among patients were myalgia (28.5%), chest pain (19%), cough (16.7%) and fever (16.7%). This is in comparison with a recent study in France, which was also conducted during the Omicron period, where cough, fever and asthenia were the three most common complaints (21). Interestingly, we found that individuals with SCD and a history of acute chest syndrome were over three times more likely to receive a COVID-19 infection diagnosis than those without such history.…”

Section: Discussioncontrasting

confidence: 55%

“…It should be noted, however, that these studies were done before the Omicron period, when Delta was the most prevalent variant. One recent prospective study in France showed less severe COVID-19 disease observed among SCD individuals during Omicron period regardless of their protection status against COVID-19 disease (21). One proposed mechanism given by Hui et al in an ex vivo study showed that Omicron has lower replication competence in human lungs, thus, causing less severe disease (22).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the effectiveness of COVID-19 vaccines in adults with sickle cell disease during the Omicron period of COVID-19 pandemic

Aldecoa,

Macaraeg,

Arsene

et al. 2024

Front. Hematol.

View full text Add to dashboard Cite

Background and aimsThe Omicron variant, one of the variants causing the coronavirus disease of 2019 (COVID-19), was first identified in November 2021 and became the predominant variant in 2022. Although causing less severe disease, this variant and its subvariants have been associated with increased transmissibility and limited protection despite vaccination and prior infection. Individuals with sickle cell disease (SCD) are particularly at greater risk of severe illness and death, and studies regarding the effectiveness of COVID-19 vaccination have been limited in this population. The study aims to determine the effectiveness of COVID-19 vaccination during this period among individuals with SCD and to examine various factors that can influence the likelihood of COVID-19 infection and severity among SCD individuals.MethodsThis is a retrospective analysis of adult patients (≥18 years) with SCD who had emergency and inpatient encounters between January 1 and December 31, 2022. Multivariable regression analysis was performed to determine the effectiveness of the COVID-19 vaccine among this population.ResultsThe study found that COVID-19 vaccination lowered the infection risk among SCD individuals by over 70% if they have received at least one dose of the vaccine. The study also found that individuals with SCD and a history of acute chest syndrome were over 3 times more likely to have a COVID-19 infection diagnosis than those without a history of acute chest syndrome.ConclusionThe study confirms the effectiveness of the COVID-19 vaccine among individuals with SCD during the Omicron period of the COVID-19 pandemic.

show abstract

Section: Discussioncontrasting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Evaluating the effectiveness of COVID-19 vaccines in adults with sickle cell disease during the Omicron period of COVID-19 pandemic

Aldecoa,

Macaraeg,

Arsene

et al. 2024

Front. Hematol.

View full text Add to dashboard Cite

show abstract

“…Second, participating HCOs are mainly large academic centers, skewing the study population. Third, loss to follow‐up is also unaccounted for in data analysis and exclusion criteria [ 22 ]. These confounding variables are not inconsequential and must be factored in when considering the generalizability of this study's results.…”

Section: Discussionmentioning

confidence: 99%

Impact of SARS‐CoV‐2 infection on pain crisis and acute chest syndrome in patients with sickle cell anemia: A retrospective multi‐cohort study based on US national data from 2020 to 2022

Alvarado,

Yerigeri,

Boakye

et al. 2024

eJHaem

View full text Add to dashboard Cite

COVID‐19 infection has been a significant contributor to global morbidity and mortality, especially among those patients with chronic diseases. The Centers for Disease Control and Prevention have classified sickle cell disease (SCD) as a condition that increases the risk of severe illness from COVID‐19 infection.A retrospective study was conducted using the TRiNetX health research network database to identify SCA patients ( HbSS, Sbeta‐thalassemia zero) who had SARS‐CoV‐2 infection over 2 years; these were compared with similar patients who did not have the infection in terms of demographics, pain control, and laboratory parametersCOVID‐19 illness impacts [ain crises and ACS, and prior vaccination against influenza and COVID‐19 may represent a protective factor for developing pain crises.

show abstract

“…vaccination in adult patients with sickle cell disease during the Omicron wave in France. 1 Derdevet et al discovered that cases with underlying sickle cell disease were infrequently infected with COVID-19, regardless of SARS-Co-V2 protective status. 1 The study focuses on adult sickle cell disease patients, a specialized and vulnerable population who may be at a higher risk of severe COVID-19 results.…”

mentioning

confidence: 99%

“…1 Derdevet et al discovered that cases with underlying sickle cell disease were infrequently infected with COVID-19, regardless of SARS-Co-V2 protective status. 1 The study focuses on adult sickle cell disease patients, a specialized and vulnerable population who may be at a higher risk of severe COVID-19 results. Understanding the effectiveness of COVID-19 vaccination in this population is critical for guiding clinical practice and public health policies.…”

mentioning

confidence: 99%

Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease: Comment

Kleebayoon

Wiwanitkit

2023

European J of Haematology

View full text Add to dashboard Cite

Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France

Cited by 4 publications

References 12 publications

Evaluating the effectiveness of COVID-19 vaccines in adults with sickle cell disease during the Omicron period of COVID-19 pandemic

Evaluating the effectiveness of COVID-19 vaccines in adults with sickle cell disease during the Omicron period of COVID-19 pandemic

Impact of SARS‐CoV‐2 infection on pain crisis and acute chest syndrome in patients with sickle cell anemia: A retrospective multi‐cohort study based on US national data from 2020 to 2022

Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease: Comment

Contact Info

Product

Resources

About